Strides Arcolab announced that its wholly owned subsidiary Strides Pharma Global Pte. Ltd. Singapore (Strides Pharma Global) has been awarded “International Headquarters Status” by the Singapore Economic Development Board (EDB).
Strides Pharma Global proposes to carry out activities for its international business including business development and planning, sales and marketing, intellectual property management, global supply chain management and global regulatory affairs.
Mohan Kumar, Chief Executive Officer Strides Pharma Global said, “We are delighted to collaborate with EDB for housing our international business. Singapore was selected as the international headquarters after assessing various options. Strides Pharma Global, Singapore will also be building a new manufacturing facility in Singapore in the next couple of years with focus on the regulated and South East Asia markets”.
“We welcome Strides’ decision to establish its international headquarters and manufacturing facility in Singapore,” said Kevin Lai, Executive Director, Biomedical Sciences and Consumer Businesses of the Singapore Economic Development Board (EDB). Singapore’s status as a trusted location, with good talent and strong connectivity to the region, enables companies to gain easy access to key regional and global markets. Strides’ decision is a strong endorsement of our commitment to build a diversified and vibrant biomedical sciences hub for Asia and beyond.